The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
Open accessAbstract
OBJECTIVE: In addition to improve glucose intolerance, recent studies suggest that glucagon-like peptide-1 (GLP-1) receptor agonism also decreases triglyceride (TG) levels. The aim of this study was to evaluate the effect of GLP-1 receptor agonism on very-low-density lipoprotein (VLDL)-TG production and liver TG metabolism. EXPERIMENTAL APPROACH: The GLP-1 peptide analogues CNTO3649 and exendin-4 were continuously administered subcutaneously to high fat diet-fed APOE*3-Leiden transgenic mice. After 4 weeks, hepatic VLDL production, lipid content, and expression profiles of selected genes involved in lipid metabolism were determined. RESULTS: CNTO3649 and exendin-4 reduced fasting plasma glucose (up to -30% and -28% respectively) and insulin (-43% and -65% respectively). In addition, these agents reduced VLDL-TG production (-36% and -54% respectively) and VLDL-apoB production (-36% and -43% respectively), indicating reduced production of VLDL particles rather than reduced lipidation of apoB. Moreover, they markedly decreased hepatic content of TG (-39% and -55% respectively), cholesterol (-30% and -55% respectively), and phospholipids (-23% and -36% respectively), accompanied by down-regulation of expression of genes involved in hepatic lipogenesis (Srebp-1c, Fasn, Dgat1) and apoB synthesis (Apob). CONCLUSION: GLP-1 receptor agonism reduces VLDL production and hepatic steatosis in addition to an improvement of glycemic control. These data suggest that GLP-receptor agonists could reduce hepatic steatosis and ameliorate dyslipidemia in patients with type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent research conducted by Parlevliet et al. 55 substantiates this point while also revealing both DPP-1i (exendin-4) and GLP1-RA result in decreased hepatic lipogenesis among mice consuming high-fat diets.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They also discovered that treatment with GLP-1 suppresses the activity of genes participating in lipogenesis.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [55]
In the citing paper
“It has been proposed that GLP-1RA ameliorate hepatic steatosis by increasing fatty acid oxidation, enhancing very-low-density lipoprotein (VLDL) secretion and inhibiting lipogenesis [170,180].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 2×
“Hepatic lipid content Liver lipids were extracted according to a modified protocol from Bligh and Dyer [21].”
MethodMechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“Type 2 diabetes mellitus (T2DM) has become a major metabolic disorder in both developed and developing countries, with impaired glucose tolerance and insulin resistance as hallmarks [1,2].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“However, therapeutic application of GLP-1 is hampered due to its short circulating halflife (,2 minutes), because it is rapidly degraded by dipeptidyl peptidase 4 (DPP-4) that is widely expressed in endothelium and intestinal mucosa [10].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Since uptake of TG from the diet eventually contributes to VLDL-TG production [37,38], reduced chylomicron production may contribute to the observed effect of GLP-1 receptor agonism on hepatic VLDL production.”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 1×
“Type 2 diabetes mellitus (T2DM) has become a major metabolic disorder in both developed and developing countries, with impaired glucose tolerance and insulin resistance as hallmarks [1,2].”
BackgroundA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Additionally, GLP-1 exerts multiple other effects, including inhibition of food intake [7], slowing gastric emptying [8], and inhibition of glucagon secretion [9].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 2×
“GLP-1 is an incretin hormone produced by intestinal L cells and the brain [4,5].”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“with earlier reports that GLP-1 and its analogs ameliorate wholebody glucose intolerance in obese animal models [23,24] and in T2DM patients [25].”
BackgroundSeparation of plasma lipoproteins by density-gradient ultracentrifugation
Redgrave, T. G., Roberts, D. C. K., & West, C. E. (1975) · Analytical Biochemistry · doi:10.1016/0003-2697(75)90488-1 · Cited by 1,107 · cited 1×
“At 120 min, mice were euthanized, and blood was collected by orbital puncture for isolation of VLDL by density gradient ultracentrifugation [19].”
MethodKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 13×
“It is known that the contribution of de novo lipogenesis to total hepatic VLDL secretion strongly increases from 2–5% under healthy conditions up to 25– 30% in T2DM patients with hepatic steatosis [28,29].”
BackgroundInfluentialTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“Additionally, GLP-1 exerts multiple other effects, including inhibition of food intake [7], slowing gastric emptying [8], and inhibition of glucagon secretion [9].”
BackgroundLarsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663 · cited 1×
“GLP-1 is an incretin hormone produced by intestinal L cells and the brain [4,5].”
BackgroundHyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP
Lin, J., Yang, R., Tarr, P. T., Wu, P.-H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P., et al. (2005) · Cell · doi:10.1016/j.cell.2004.11.043 · Cited by 625
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · cited 1×
“GLP-1 is released in response to food intake to stimulate glucose-dependent insulin secretion by the pancreas [4,6].”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 1×
“This corroborates recent studies showing that prolonged infusion of exendin-4 in ob/ob mice reduced hepatic TG accumulation [27].”
ResultManagement of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · cited 1×
“Additionally, GLP-1 exerts multiple other effects, including inhibition of food intake [7], slowing gastric emptying [8], and inhibition of glucagon secretion [9].”
BackgroundInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480 · cited 1×
“Finally, circulating GLP-1 can cross the blood-brain barrier [39] and GLP-1 receptors are abundantly expressed in many brain areas [40].”
BackgroundGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“Finally, circulating GLP-1 can cross the blood-brain barrier [39] and GLP-1 receptors are abundantly expressed in many brain areas [40].”
BackgroundAalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450 · cited 1×
“After 30 min, the animals received an iv injection of tyloxapol (500 mg/ kg body weight; Triton WR-1339, Sigma), as a 10% (w/w) solution in sterile saline, to prevent systemic lipolysis of newly secreted hepatic VLDL-TG [18].”
MethodDiraison, F., Moulin, P., & Beylot, M. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70061-7 · Cited by 435 · cited 1×
“It is known that the contribution of de novo lipogenesis to total hepatic VLDL secretion strongly increases from 2–5% under healthy conditions up to 25– 30% in T2DM patients with hepatic steatosis [28,29].”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · cited 1×
“Interestingly, it has recently been established that human hepatocytes [32,33] as well as rodent hepatocytes [34] express GLP-1 receptors.”
BackgroundLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350 · cited 1×
“be superior to those of exenatide (duration of action ,24 hours) and in addition will lead to better tolerability due to the necessity of injecting once daily only as compared to twice daily for exenatide [44].”
BackgroundNonalcoholic Fatty Liver Disease: A Review and Update
Lewis, J. R., & Mohanty, S. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1081-0 · Cited by 345 · cited 1×
“hepatic steatosis) [3], for which no effective pharmacotherapeutic options are yet available.”
BackgroundMatikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336 · cited 1×
“Third, GLP-1 receptor agonism by exendin-4 or the DPP-4 inhibitor sitagliptin reduces the intestinal production of chylomicron-TG and apoB in hamsters [35], and the DPP-4 inhibitor vildagliptin reduces postprandial chylomicron-TG and apoB in T2DM patients [36].”
BackgroundMulvihill, E. E., Allister, E. M., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Markle, J. M., Hegele, R. A., & Huff, M. W. (2009) · Diabetes · doi:10.2337/db09-0634 · Cited by 297 · cited 1×
“2D) compared to chow diet, which is in line with a previous study [22].”
ResultHsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2010) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 275 · cited 1×
“Third, GLP-1 receptor agonism by exendin-4 or the DPP-4 inhibitor sitagliptin reduces the intestinal production of chylomicron-TG and apoB in hamsters [35], and the DPP-4 inhibitor vildagliptin reduces postprandial chylomicron-TG and apoB in T2DM patients [36].”
BackgroundBarrows, B. R., & Parks, E. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1709 · Cited by 272 · cited 1×
“Since uptake of TG from the diet eventually contributes to VLDL-TG production [37,38], reduced chylomicron production may contribute to the observed effect of GLP-1 receptor agonism on hepatic VLDL production.”
BackgroundDiet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
van Vlijmen, B. J., van den Maagdenberg, A. M., Gijbels, M. J., van der Boom, H., HogenEsch, H., Frants, R. R., Hofker, M. H., & Havekes, L. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117117 · Cited by 250 · cited 1×
“Therefore, the objective of the present study was to evaluate the effects of GLP-1 receptor agonism via CNTO3649 and exendin-4 on VLDL-TG production and liver TG metabolism, and further to explore the underlying mechanisms, in APOE*3-Leiden (E3L) transgenic mice fed a high fat diet (HFD) [15].”
BackgroundSelf-citationTransgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia
van den Maagdenberg, A. M., Hofker, M. H., Krimpenfort, P. J., de Bruijn, I., van Vlijmen, B., van der Boom, H., Havekes, L. M., & Frants, R. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82232-3 · Cited by 229 · cited 1×
“Animals For all experiments, 8–10 weeks old male E3L mice [16] were used, housed in a temperature and humidity-controlled environment with free access to food and water.”
MethodSelf-citationNogueiras, R., Pérez-Tilve, D., Veyrat-Durebex, C., Morgan, D. A., Varela, L., Haynes, W. G., Patterson, J. T., Disse, E., Pfluger, P. T., López, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5977-08.2009 · Cited by 182 · cited 1×
“on hepatic glucose output [41] and lipid deposition in white adipose tissue [42].”
BackgroundAdiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000226115.97436.c0 · Cited by 173
Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin
Viswanathan, P., Chaudhuri, A., Bhatia, R., Al-Atrash, F., Mohanty, P., & Dandona, P. (2007) · Endocrine Practice · doi:10.4158/ep.13.5.444 · Cited by 142 · cited 13×
“It is known that the contribution of de novo lipogenesis to total hepatic VLDL secretion strongly increases from 2–5% under healthy conditions up to 25– 30% in T2DM patients with hepatic steatosis [28,29].”
BackgroundInfluentialEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124 · cited 1×
“How do the present data obtained in E3L mice translate to clinical practice? Recently, it has been reported that treatment of T2DM patients with exenatide on top of pioglitazone resulted in a greater decrease in both hepatic TG and plasma TG levels compared to treatment with pioglitazone only [43].”
Li, X., Catalina, F., Grundy, S. M., & Patel, S. B. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37649-5 · Cited by 112
Parlevliet, E. T., van Weenen, J. E. D. L., Romijn, J. A., & Pijl, H. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00191.2010 · Cited by 85 · cited 1×
“on hepatic glucose output [41] and lipid deposition in white adipose tissue [42].”
BackgroundSelf-citationGedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 82 · cited 1×
“with earlier reports that GLP-1 and its analogs ameliorate wholebody glucose intolerance in obese animal models [23,24] and in T2DM patients [25].”
BackgroundHellerstein, M. K., Neese, R. A., & Schwarz, J. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.265.5.e814 · Cited by 56 · cited 1×
“It is known that the contribution of de novo lipogenesis to total hepatic VLDL secretion strongly increases from 2–5% under healthy conditions up to 25– 30% in T2DM patients with hepatic steatosis [28,29].”
BackgroundGLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes
Tomás, E., Stanojevic, V., & Habener, J. F. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1253421 · Cited by 54 · cited 12×
“The high dose of CNTO3649 and both doses of exendin4 decreased the expression of Srebp-1c (253%, P,0.05, and up to 275%, P,0.05, respectively) (Fig.”
BackgroundInfluentialGreen, B. D., Lavery, K. S., Irwin, N., O’Harte, F. P. M., Harriott, P., Greer, B., Bailey, C. J., & Flatt, P. R. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097824 · Cited by 49 · cited 1×
“with earlier reports that GLP-1 and its analogs ameliorate wholebody glucose intolerance in obese animal models [23,24] and in T2DM patients [25].”
BackgroundPicha, K. M., Cunningham, M. R., Drucker, D. J., Mathur, A. S., Ort, T., Scully, M. S., Soderman, A. R., Spinka-Doms, T., Stojanovic-Susulic, V., Thomas, B. A., et al. (2008) · Diabetes · doi:10.2337/db07-1775 · Cited by 41 · cited 5×
“The long-acting GLP-1 analogue CNTO3649, a more recent version of CNTO736 with two point mutations introduced to improve protein solubility, retains this advantageous pharmacokinetic profile.”
MethodSelf-citationParlevliet, E. T., der Elst, J. P. S.-V., Corssmit, E. P. M., Picha, K. M., O’Neil, K. T., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., & Pijl, H. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144154 · Cited by 34 · cited 2×
“In our previous study, in which we administered exendin-4 by daily intraperitoneal injections, we were unable to detect any effect of exendin-4 on VLDL production, albeit that exendin-4 did improve glucose tolerance [12].”
BackgroundMethodSelf-citationSterol-regulatory-element-binding protein I c mediates insulin action on hepatic gene expression
Ferré, P., Foretz, M., Azzout‐Marniche, D., Bécard, D., & Foufelle, F. (2001) · Biochemical Society Transactions · doi:10.1042/bst0290547 · Cited by 33 · cited 1×
“Since Srebp-1c plays a crucial role in insulinmediated de novo lipogenesis in the liver [30], it is well possible that the improved HFD-induced glucose intolerance accompanied by reduced insulin levels resulted in downregulation of hepatic Srebp1c expression, thereby attenuating the HFD-induced increase in de novo lip…”
BackgroundExenatide (Byetta) for type 2 diabetes.
(2005) · PubMed · Cited by 7
Cited by
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
“In high-fat dietfed ApoE*3-Leiden CETP-transgenic mice, GLP1-R agonist treatment decreased hepatic steatosis and plasma TG by respectively decreasing DNL and VLDL production [187].”
BackgroundAnti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Arguello, G., Balboa, E., Arrese, M., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306
Lipid Processing in the Brain: A Key Regulator of Systemic Metabolism
Bruce, K. D., Zsombok, A., & Eckel, R. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00060 · Cited by 262
Metadata
- Authors
- Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., Pijl, H., & Rensen, P. C. N.
- Affiliations
- Leiden University Medical Center (NL)
- Janssen Research & Development (United States) (US)
- Netherlands Organisation for Applied Scientific Research (NL)
- Corresponding author
- Rensen, Patrick C. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-11-02
- Volume
- 7
- Issue
- 11
- Pages
- e49152
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3487842
- OpenAlex
- W2139855450
- Cited by
- 97
- References
- 45
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 2 · 2018: 5 · 2017: 13 · 2016: 5 · 2015: 8 · 2014: 11 · 2013: 5
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TNO Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- GLP-1 receptor agonism, glucagon-like peptide-1, VLDL production, hepatic steatosis, hepatic lipogenesis, exendin-4, APOE*3-Leiden mice, high-fat diet, dyslipidemia, type 2 diabetes, hepatic triglyceride metabolism, apolipoprotein B, SREBP-1c, fatty acid synthase, insulin, glycemic control
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Apolipoproteins B, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Liver, Insulin, Liver, Male, Mice, Transgenic, Peptides, Venoms, Receptors, Glucagon, Lipogenesis, Dyslipidemias, Mice, Glucagon-Like Peptide 1, Apolipoprotein E3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.